InvestSMART

Imagion Biosystems Limited (ASX:IBX)

ALERT: Price-sensitive ASX Announcement for IBX
Current share price for IBX : $0.013 -0.018 (-58.06%)+
Announcement
Release
21 Oct 2025 9:42AM
Price at Release
$0.031
Full Release
download
Summary
Imagion Biosystems Limited released its Appendix 4C and Quarterly Activities Report for the quarter ending 30 September 2025. The company reported a cash balance of AU$3.2 million, an increase of AU$2.4 million from the previous quarter due to funds received from a placement. Operating cash outflow was AU$0.9 million, expected to rise next quarter due to the commencement of a Phase 2 clinical study for the MagSense® HER2 Imaging Agent. The company is preparing to submit an IND application for this study to the FDA, with the study expected to begin pending approval. Payments to related parties amounted to AU$137k, primarily for Director’s fees. Imagion also updated its convertible note facility with Mercer Street Global Opportunity Fund, LLC, with the facility being partly drawn. The company believes it has sufficient funding for the upcoming quarters and is in a strong position to execute its strategic initiatives.
Key Points
  • Cash balance of AU$3.2 million as of 30 September 2025.
  • Operating cash outflow of AU$0.9 million for the quarter.
  • Preparation to submit IND application to the FDA for Phase 2 study.
  • Payments of AU$137k to related parties for Director’s fees.
  • Convertible note facility with Mercer partly drawn.
  • Sufficient funding for upcoming quarters.
  • Strong position for executing strategic initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.